Donors With Hepatitis B Surface Antigen Positivity H. Asuman Yavuza,*, S. Tekinb, Y. Yukselc, I. Ates¸d, L. Yucetine, M. Demirf, B. Uygung, M. Tuncerh, and A. Demirbasc a Department of Nephrology and Renal Transplantation, Atakent Education and Research Hospital, Acıbadem University, _Istanbul, Turkey; bDepartment of General Surgery and Transplantation Unit, Medical Park Hospital, Kemerburgaz University, Antalya, Turkey; c Department of General Surgery and Transplantation Unit, Medical Park Hospital, Antalya, Turkey; dDepartment of Cardiology, Medline BSK Lara Hospital, Antalya, Turkey; eOrgan Transplantation Coordination Unit Medical Park Hospital, Antalya, Turkey; fDepartment of Biochemistry, Medical Park Hospital, Antalya, Turkey; gDepartment of Clinical Microbiology and Infectious Disease, Medical Park Hospital, Antalya, Turkey; and hDepartment of Nephrology, Medical Park Hospital, Kemerburgaz University, Antalya, Turkey

ABSTRACT Objective. There is a still controversy among transplantation centers regarding acceptance of hepatitis B surface antigen (HBsAg)epositive donors for renal transplantation. However, some reports show that these donors can be used under a special protocol. In this study, we compared the clinical and biochemical parameters of patients who received kidneys from HBsAg-positive (group 1) versus other living-related kidney donors (group 2). Materials and Methods. We retrospectively analyzed the outcomes of 2168 living-related renal transplantations performed between December 2008 and April 2014 at Medical Park Hospital Transplantation Center, Antalya, Turkey. One hundred eleven donors were HbsAg-positive (group 1), and 2057 donors were HbsAg-negative (group 2). Group 1 kidney transplantations were undertaken only if the recipient displayed a hepatitis B antibody titer >10 mIU/mL and donor hepatitis B virus DNA was negative. Results. Demographic characteristics; 1-, 2- and 4-year serum creatinine levels; glomerular filtration rates; and liver function test results were similar between the two groups. There were no new hepatitis B virus infections throughout the study period. Acute rejection rates (26/111 in group 1 vs 375/2168 in group 2; P ¼ .887), graft loss (4/111 in group 1 vs 123/2168 in group 2; P ¼ .546), and patient loss (6/111 in group 1 vs 102/2168; P ¼ .132) were similar between the two groups. Conclusion. Our study showed that hepatitis B surface antigen positivity was not a contraindication to living-kidney donation.

A

LTHOUGH the number of cadaveric organ donors remains relatively stable, the number of patients awaiting transplantation continues to increase, creating a shortage of donor organs [1]. To create a solution, there is interest in transplanting organs formerly considered marginal or undesirable (older donors, hemodynamically unstable donors, noneheart-beating donors, and donors with markers of prior hepatitis B virus [HBV] infection) [2e6]. Whereas hepatitis B surface antigen (HBsAg) positivity has been considered to be an absolute contraindication to living-kidney donation, some studies have suggested that kidneys can be used in selected recipients without significantly effecting graft or patient outcomes. In this study we compared clinical and

biochemical parameters of patients who received kidneys from HbsAg-positive living donors (group 1) with other recipients of kidneys of HbsAg-negative donors (group 2). PATIENTS AND METHODS The study included 939 female (36 in group 1 and 903 in group 2) and 1229 male (75 in group 1 and 1154 in group 2) recipients of

*Address correspondence to Prof. Dr H. Asuman Yavuz, Acıbadem Atakent Research and Education Hospital, Halkalı Mah., Altınsehir Cad. Kucukcekmece, Istanbul, Turkey. E-mail: [email protected]

0041-1345/15 http://dx.doi.org/10.1016/j.transproceed.2015.04.014

ª 2015 by Elsevier Inc. All rights reserved. 360 Park Avenue South, New York, NY 10010-1710

1312

Transplantation Proceedings, 47, 1312e1314 (2015)

DONORS WITH HEPATITIS B

1313

living-related kidney transplantations performed between 2008 and 2013. Group 1 kidney transplantation required recipients’ hepatitis B surface antibody (anti-HBs) titer to be 10 mIU/mL and donor HBV DNA to be negative. Recipients whose anti-HBs was

Donors With Hepatitis B Surface Antigen Positivity.

There is a still controversy among transplantation centers regarding acceptance of hepatitis B surface antigen (HBsAg)-positive donors for renal trans...
242KB Sizes 1 Downloads 11 Views